Holen Sie sich die Stockscreener-App
43.05
1.69%
-0.74
Vorhandelsmarkt:
43.00
-0.05
-0.12%
Schlusskurs vom Vortag:
$43.79
Offen:
$44.64
24-Stunden-Volumen:
1.13M
Relative Volume:
1.28
Marktkapitalisierung:
$3.33B
Einnahmen:
$13.17M
Nettoeinkommen (Verlust:
$-199.06M
KGV:
-15.71
EPS:
-2.74
Netto-Cashflow:
$-156.53M
1W Leistung:
-3.42%
1M Leistung:
+4.62%
6M Leistung:
+11.41%
1J Leistung:
+19.52%
1-Tages-Spanne:
$42.31
$44.64
1-Wochen-Bereich:
$41.32
$46.99
52-Wochen-Spanne:
$26.74
$46.99
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Firmenname
Xenon Pharmaceuticals Inc
Sektor
Branche
Telefon
(604) 484-3300
Adresse
200 - 3650 GILMORE WAY, BURNABY
Compare XENE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
43.05 | 3.38B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-03 | Fortgesetzt | Wells Fargo | Overweight |
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-04 | Eingeleitet | Citigroup | Buy |
| 2023-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Eingeleitet | Goldman | Buy |
| 2022-12-12 | Eingeleitet | Cowen | Outperform |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-10-19 | Eingeleitet | Raymond James | Outperform |
| 2022-08-29 | Eingeleitet | BofA Securities | Buy |
| 2022-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-21 | Eingeleitet | Needham | Buy |
| 2020-06-01 | Fortgesetzt | Jefferies | Buy |
| 2020-03-25 | Eingeleitet | Wedbush | Outperform |
| 2020-01-08 | Eingeleitet | William Blair | Outperform |
| 2019-09-20 | Eingeleitet | Guggenheim | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2017-03-13 | Eingeleitet | Jefferies | Buy |
| 2016-10-21 | Eingeleitet | Stifel | Buy |
| 2016-09-26 | Eingeleitet | Guggenheim | Buy |
| 2016-04-14 | Bestätigt | Jefferies | Buy |
| 2015-10-30 | Fortgesetzt | Jefferies | Buy |
| 2014-12-02 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Xenon Pharmaceuticals Inc Aktie (XENE) Neueste Nachrichten
Investors Purchase High Volume of Xenon Pharmaceuticals Call Options (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - MarketBeat
Aug Selloffs: Does Xenon Pharmaceuticals Inc stock have upside surprise potentialJuly 2025 Short Interest & Long Hold Capital Preservation Plans - baoquankhu1.vn
Xenon awaiting critical epilepsy drug study results that could lead to FDA approval - The Globe and Mail
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - Defense World
Xenon Pharmaceuticals Refreshes $400 Million ATM Equity Program - TipRanks
Xenon Pharmaceuticals registers $400M of common shares for ATM offering - TradingView
Xenon Pharmaceuticals (XENE) refreshes $400,000,000 ATM share program - Stock Titan
Xenon Pharmaceuticals (NASDAQ: XENE) registers up to $400M ATM equity offering - Stock Titan
Needham & Company LLC Issues Positive Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price - MarketBeat
Wells Fargo & Company Issues Positive Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 12-Month HighWhat's Next? - MarketBeat
Wedbush Adjusts Xenon Pharmaceuticals PT to $47 From $44, Maintains Outperform Rating - marketscreener.com
Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus - Finviz
Xenon Pharmaceuticals stock hits 52-week high at $46.68 - Investing.com
Xenon Pharmaceuticals stock hits 52-week high at $46.68 By Investing.com - Investing.com Canada
Westfield Capital Management Co. LP Boosts Stake in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals XENE Loss Widening Tests Bullish Pipeline Narrative - Sahm
Decoding Xenon Pharmaceuticals Inc (XENE): A Strategic SWOT Insi - GuruFocus
Xenon Pharmaceuticals (NASDAQ:XENE) Posts Quarterly Earnings Results, Misses Expectations By $0.11 EPS - MarketBeat
Xenon Pharmaceuticals: Fourth Quarter Earnings Overview - Bitget
Xenon Pharmaceuticals: Q4 Earnings Snapshot - Barchart.com
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update - Yahoo Finance
JPMorgan Chase & Co. Buys 142,452 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
XENE Technical Analysis & ETF Price Forecast - Intellectia AI
Xenon Pharmaceuticals (NASDAQ:XENE) Earns Outperform Rating from Analysts at Wolfe Research - Defense World
Xenon earnings loom as investors brace for Phase 3 catalyst By Investing.com - Investing.com Canada
Xenon Pharmaceuticals (NASDAQ:XENE) Upgraded at Wolfe Research - MarketBeat
Xenon Pharmaceuticals Inc. (XENE) Investor Outlook: Analyzing a 30% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
A Look At Xenon Pharmaceuticals (XENE) Valuation After Wolfe Research’s New Favorable Coverage - Yahoo Finance
Wolfe Research initiates Xenon Pharmaceuticals stock coverage with outperform rating - Investing.com Nigeria
XENE: Xenon Pharmaceuticals Coverage Initiated by Wolfe Research - GuruFocus
Wolfe Research Initiates Coverage of Xenon Pharmaceuticals (XENE) with Outperform Recommendation - Nasdaq
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million - The Motley Fool
Investment Review: Will DRMA stock go up in YEAR2025 Winners & Losers & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Will Xenon Pharmaceuticals Inc. stock benefit from green energy trends2025 Fundamental Recap & Risk Controlled Daily Plans - mfd.ru
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Is Xenon Pharmaceuticals (NASDAQ:XENE) Rising In The Nasdaq Index - Kalkine Media
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data - Nasdaq
Xenon Pharmaceuticals (XENE) Projected to Post Earnings on Thursday - MarketBeat
Is Xenon Pharmaceuticals Inc. a speculative investmentJuly 2025 Rallies & Weekly Market Pulse Alerts - mfd.ru
Aberdeen Group plc Has $23.25 Million Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Understanding Momentum Shifts in (XENE) - Stock Traders Daily
How Xenon Pharmaceuticals Inc. stock reacts to global recession fearsInsider Buying & Safe Swing Trade Setups - mfd.ru
Activity Recap: Is Xenon Pharmaceuticals Inc stock undervalued right nowWeekly Trade Summary & Fast Moving Market Watchlists - baoquankhu1.vn
Is Xenon Pharmaceuticals Inc. stock a safe haven assetIPO Watch & Precise Swing Trade Entry Alerts - mfd.ru
Xenon Pharmaceuticals (NASDAQ:XENE) Share Price Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat
How Xenon Pharmaceuticals Inc. stock responds to policy changesJuly 2025 Levels & Real-Time Price Movement Reports - mfd.ru
Xenon Pharma To Report Epilepsy Trial Results Next Month - RTTNews
Is Xenon Pharmaceuticals Inc. a strong candidate for buy and holdPortfolio Gains Report & Fast Gaining Stock Reports - mfd.ru
Xenon Pharmaceuticals Inc. (XENE) Investor Outlook: Strong Buy Ratings and 31.57% Potential Upside - DirectorsTalk Interviews
Finanzdaten der Xenon Pharmaceuticals Inc-Aktie (XENE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):